Melinta Therap Drug Patent Portfolio
Melinta Therap owns 2 orange book drugs protected by 5 US patents Given below is the list of Melinta Therap's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649352 | High purity oritavancin and method of producing same | 16 Jul, 2035 | Active |
| US9682061 | Methods of treating bacterial infections using oritavancin | 26 Apr, 2030 | Active |
| US8420592 | Methods of treatment using single doses of oritavancin | 29 Aug, 2029 | Active |
| US5840684 | Glycopeptide antibiotic derivatives | 24 Nov, 2020 | Expired |
| US5998581 | Reductive alkylation of glycopeptide antibiotics | 12 Nov, 2017 | Expired |
Latest Legal Activities on Melinta Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Melinta Therap.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9682061 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9649352 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9649352 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9682061 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2020 | US8420592 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2020 | US8420592 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Jun, 2017 | US9682061 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Jun, 2017 | US9682061 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Jun, 2017 | US9682061 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Jun, 2017 | US9682061 |
|
Email Notification
Critical
| 01 Jun, 2017 | US9682061 |
|
Email Notification
Critical
| 01 Jun, 2017 | US9682061 |
|
Issue Notification Mailed
Critical
| 31 May, 2017 | US9682061 |
|
Issue Notification Mailed
Critical
| 31 May, 2017 | US9682061 |
|
Recordation of Patent Grant Mailed
Critical
| 16 May, 2017 | US9649352 |
Melinta Therap Drug Patents' Oppositions Filed in EPO
Melinta Therap drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 13, 2017, by Prüfer & Partner Mbb. This opposition was filed on patent number EP09810708A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP09810708A | Jan, 2017 | Prüfer & Partner mbB | Granted and Under Opposition |
Melinta Therap's Family Patents
Melinta Therap Drug List
Given below is the complete list of Melinta Therap's drugs and the patents protecting them.
1. Kimyrsa
Kimyrsa is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649352 | High purity oritavancin and method of producing same |
16 Jul, 2035
(10 years from now)
| Active |
| US9682061 | Methods of treating bacterial infections using oritavancin |
26 Apr, 2030
(5 years from now)
| Active |
| US8420592 | Methods of treatment using single doses of oritavancin |
29 Aug, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kimyrsa's drug page
2. Orbactiv
Orbactiv is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649352 | High purity oritavancin and method of producing same |
16 Jul, 2035
(10 years from now)
| Active |
| US9682061 | Methods of treating bacterial infections using oritavancin |
26 Apr, 2030
(5 years from now)
| Active |
| US8420592 | Methods of treatment using single doses of oritavancin |
29 Aug, 2029
(4 years from now)
| Active |
| US5840684 | Glycopeptide antibiotic derivatives |
24 Nov, 2020
(3 years ago)
| Expired |
| US5998581 | Reductive alkylation of glycopeptide antibiotics |
12 Nov, 2017
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orbactiv's drug page